Date: 2013-01-03
Type of information: Licensing agreement
Compound: CMV dense body project (human cytomegalovirus (CMV) vaccine)
Company: CEVEC Pharmaceuticals (Germany) Vakzine Projekt Management (Germany)
Therapeutic area: Infectious diseases
Type agreement: licensing
Action mechanism:
Disease: prevention of cytomegalovirus infection
Details: CEVEC Pharmaceuticals, the developer of the CAP® Technology, a novel human expression system derived from amniocytes, and VPM – Vakzine Projekt Management GmbH, have concluded an exclusive license agreement on VPM’s proprietary human CMV dense body technology.
CAP® Technology is based on an immortalized human cell line for vaccine and protein production developed by CEVEC for industrial use. The serum-free suspension culture of this proprietary cell line allows for high virus yields for a broad variety of human pathogenic viruses. CAP® cells are uniquely suited to produce vaccines against challenging viral targets like human CMV. The non-infectious dense bodies are considered to be one of the most promising new CMV vaccine approaches since they result in efficient and long-lasting immunity. The CMV dense body project is foreseen to enter clinical development within the next 18 months. CEVEC receives exclusive word-wide development and commercialization rights from VPM and VPM will substantially contribute by taking over development project management services for the project.
Financial terms:
Latest news:
